DSP-0509, a systemically available TLR7 agonist, exhibits combination effect with immune checkpoint blockade by activating anti-tumor immune effects

DSP-0509, a systemically available TLR7 agonist, exhibits combination effect with immune checkpoint blockade by activating anti-tumor immune effects

TLR7 is an innate immune receptor that recognizes single-stranded RNAs, and its activation leads to anti-tumor immune effects. Although it is the only approved TLR7 agonist in cancer therapy, imiquimod is allowed to be administered with topical formulation. Thus, systemic administrative TLR7 agonist...

Full description

Bibliographic Details
Main Authors: Yosuke Ota, Yasuhiro Nagai, Yuko Hirose, Seiji Hori, Erina Koga-Yamakawa, Ken Eguchi, Kentaro Sumida, Masashi Murata, Hiroki Umehara, Setsuko Yamamoto
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Immunology
Subjects:
TLR7 agonist
DSP-0509
check point blocker
combination
effector memory T cell
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1055671/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1055671/full

Similar Items